NRIX - Latest News

Nurix Therapeutics, Inc. (NRIX), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $1.98B. Beta to the broader market is 1.87.

The article list below shows the most recent NRIX headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent NRIX Headlines

Nurix Stock Up 29% in a Month: Here's What You Should Know

zacks.com - Jun 26, 2026

NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2. 3

Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?

zacks.com - Jun 26, 2026

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estima

Nurix Therapeutics Deal With Roche Is Worth Betting On

seekingalpha.com - Jun 11, 2026

Recently, Nurix secured a partnership with Roche, which I believe has substantially derisked the stock as a whole. Similarly, this deal helps validat

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy

globenewswire.com - Jun 11, 2026

High objective response rate of 92. 9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment U

Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions

seekingalpha.com - Jun 9, 2026

Nurix Therapeutics, Inc. remains a Strong Buy as bexobrutideg advances in pivotal r/r CLL trials and secures a transformative $2.

How News Affects NRIX Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track NRIX's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked NRIX news questions

What is the latest NRIX news headline?

The most recent NRIX headline (Jun 26, 2026) is "Nurix Stock Up 29% in a Month: Here's What You Should Know". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the NRIX news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What NRIX news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual NRIX options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.